The disposition of the b-blocking drug talinolol is controlled by P-glycoprotein in man. Because talinolol is marketed as a racemate, we reevaluated the serum-concentration time pro®les of talinolol of a previously published study with single intravenous (30 mg) and repeated oral talinolol (100 mg f
Elucidation of the structure of talinolol metabolites in man determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
✍ Scribed by R. Oertel; K. Richter; B. Trausch; A. Berndt; T. Gramatté; W. Kirch
- Publisher
- Elsevier Science
- Year
- 1994
- Weight
- 750 KB
- Volume
- 660
- Category
- Article
- ISSN
- 0378-4347
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In an open randomized crossover study, the pharmacokinetics and bioavailability of the selective P1-adrenoceptor antagonist talinolol (CordanumB -Arzneimittelwerk Dresden GmbH, Germany) were investigated in twelve healthy volunteers (five female, seven male; three poor and nine extensive metabolizer
The absorption of talinolol (TA) 50 mg was investigated without and together with the co-administration of sulfasalazine (SASP) 4 g in 11 healthy young volunteers, in order to clarify gastrointestinal transit of TA. Without SASP, the tmax of TA was 2.8 h, Cmax was 112 ng.ml-1 and the half life was 1
A new specific HPLC-TSP-MS/MS assay for identification of b-blocking drug talinolol and its metabolites in urinary samples of man, dog, rat and mouse after single oral administration has been developed. Centrifuged udnes were directly injected into the HPLC-TSP-MS system. Based on thermospray MS/MS